A5025707585- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Myasthenia Gravis and Thymoma
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Nutrition and Health in Aging
- Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
Shizuoka Cancer Center
2016-2025
Japanese Foundation For Cancer Research
2017
Kobe City Medical Center General Hospital
2016
Kyoto University
2016
Eli Lilly (Japan)
2009-2016
Guangzhou Medical University
2016
Cancer Genetics (United States)
2014
Northwestern Medicine
2014
Juntendo University
2013
Thoracic Surgery Foundation
2012-2013
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but not a known mechanism of resistance to EGFR inhibitors. HER3-DXd an antibody-drug conjugate consisting HER3 antibody attached topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic non-small cell cancer (NSCLC) prior tyrosine (TKI) therapy. Among 57 receiving 5.6 mg/kg...
Abstract Serum levels of amphiregulin and transforming growth factor-α (TGF-α), which were identified previously to be expressed at high in non–small cell lung cancer (NSCLC) with poor response gefitinib, examined by ELISA using blood samples taken from 50 patients advanced NSCLCs. Of 14 cases that revealed above the cutoff line for serum, 12 responded poorly whereas 18 36 showing below partial (PR) or stable disease (SD; P = 0.026). Thirteen 15 who positive TGF-α 35 negative turned out...
Enumeration of circulating tumor cells (CTCs) may be valuable for prognostic assessment in lung cancer patients. In this study, we report the clinical significance CTCs small cell (SCLC).In total, 51 consecutive patients newly diagnosed as having SCLC and starting chemotherapy or chemoradiotherapy were prospectively enrolled. Blood samples drawn at baseline, after chemotherapy, relapse. isolated using CellSearch System (Veridex LLC). Thresholds 1 to 100 baseline systematically correlated...
To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with monotherapy, in patients advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations.Chemotherapy-naïve for NSCLC from China, Japan, Korea, Taiwan (35 sites) advanced, EGFR-mutant, NS were randomly assigned (2:1; computer-generated, interactive voice response) open-label (500 mg/m(2) on day 1 every 21-day cycle) plus...
Background Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, colon, and prostate cancer. However, poor sensitivity been reported for non-small lung cancer (NSCLC). To address this problem, we developed a microcavity array (MCA) system integrated miniaturized device CTC isolation without relying on EpCAM expression. Here, report the results clinical study CTCs which compared...
The usefulness of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) positron emission tomography (PET) can help predict the grade malignancy and staging in thymic epithelial tumors. However, no satisfactory biologic explanation exists for this phenomenon. aim study was to investigate underlying mechanisms [(18)F]FDG uptake.Forty-nine patients with tumors who underwent PET were included study. Tumor sections stained by immunohistochemistry glucose transporter 1 (GLUT1), 3 (GLUT3),...
The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non-small-cell lung cancer. Several EGFR inhibitors (TKIs) are currently approved, and both gefitinib erlotinib the most well-known first-generation EGFR-TKIs. This randomized phase III study was conducted to investigate difference between these two EGFR-TKIs.Previously treated patients with adenocarcinoma were randomly assigned receive or erlotinib. aimed noninferiority of compared primary end point...
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because only a small percentage enrolled in the clinical trials to evaluate tumors EGFR mutation were NSCLC. A pooled analysis was conducted clarify NSCLC mutations. systematic search PUBMED databases identify all reports that contained advanced and treated gefitinib. selected who described containing data histology, status...
9504 Background: T-DXd is an antibody-drug conjugate composed of anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. In a phase trial, patients (pts) with HER2-mutated NSCLC who received had confirmed objective response rate (ORR) 72.7% (8/11) (Tsurutani et al, WCLC 2018). DESTINY-Lung01 (NCT03505710) ongoing, multicenter, II study in pts non-squamous overexpressing HER2 or containing HER2-activating mutation. We report data for the cohort...
Although third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitors ( EGFR ‐ TKI ) can overcome T790M‐mediated resistance in non‐small‐cell lung cancer NSCLC ), rebiopsy to confirm T790M status is occasionally difficult. We aimed investigate the current tendency and limitations of clinical practice. This study included 139 consecutive patients with mutations, who had experienced progressive disease PD after treatment. retrospectively reviewed patient characteristics, tumor...
Background PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line NSCLC high expression. Bevacizumab enhanced cytotoxic agent and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in non-squamous (NS)-NSCLC, antibodies preclinical models. Methods This single-arm phase II study investigated clinical benefits...
Background HER3 is broadly expressed in NSCLC and the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting a antibody attached to topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker. U31402-A-U102 ongoing phase 1 study HER3-DXd patients with advanced NSCLC. Patients EGFR-mutated that progressed after EGFR TKI platinum-based chemotherapy (PBC) who received 5.6 mg/kg intravenously once every 3 weeks had confirmed objective response rate (cORR)...
Abstract Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, SEZ6-targeted antibody conjugated to calicheamicin, was evaluated phase I study (NCT03639194) patients with relapsed/refractory SCLC. We report initial outcomes of ABBV-011 monotherapy. Patients and Methods: administered intravenously once every 3 weeks during dose escalation (0.3–2 mg/kg) expansion. SEZ6-positive tumors (≥25% tumor cells ≥1+ staining intensity...